Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGIR | P43119 | 14/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7517849 | 0.88 | KDM4E (0.44) | DDB1CRBNKDM4EPOLBPTGIR | |
| SCHEMBL7665918 | 0.86 | LMNA (0.49) | DDB1CRBNLMNAKDM4EPOLB | |
| SCHEMBL7383487 | 0.77 | ABCB1 (0.52) | DDB1CRBNKDM4EPOLBPTGIR | |
| SCHEMBL6957074 | 0.77 | MAPT (0.59) | LMNAKDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL7517734 | 0.77 | ALDH1A1 (0.44) | LMNAKDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL7962763 | 0.77 | LMNA (0.42) | LMNAKDM4EPOLBMAPTALDH1A1 | |
| SCHEMBL7525144 | 0.75 | PTGDR2 (0.40) | DDB1CRBNKDM4EPOLBPTGDR2 | |
| SCHEMBL1839684 | 0.75 | MRGPRX4 (0.63) | KDM4EPOLBPTGIRPTGDRPTGDR2 | |
| SCHEMBL28550871 | 0.75 | MRGPRX4 (0.60) | KDM4EPOLBPTGIRPTGDRPTGDR2 | |
| SCHEMBL8460607 | 0.72 | PTPN1 (0.49) | LMNAKDM4EMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | DDB1 3635/4885CRBN 4007/4885LMNA 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.